Anebulo Pharmaceuticals Inc Market Cap ($13.52 Million)
Market Cap & Net Worth: Anebulo Pharmaceuticals Inc (ANEB)
Anebulo Pharmaceuticals Inc market cap. Anebulo Pharmaceuticals Inc (NASDAQ:ANEB) has a market capitalization of $13.52 Million ($13.52 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26154 globally and #5491 in its home market, demonstrating a -15.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anebulo Pharmaceuticals Inc's stock price $0.33 by its total outstanding shares 40784731 (40.78 Million). Also see Anebulo Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Anebulo Pharmaceuticals Inc Market Cap History (2021–2026)
Anebulo Pharmaceuticals Inc market cap history from 2021 to 2026. Data shows change from $250.83 Million to $13.52 Million (-43.55% CAGR). Check current stock price of Anebulo Pharmaceuticals Inc for real-time trading data and today's change.
Index Memberships
Anebulo Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #729 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2389 of 3165 |
Weight: Anebulo Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Anebulo Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anebulo Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Anebulo Pharmaceuticals Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANEB by Market Capitalization
Companies near Anebulo Pharmaceuticals Inc in the global market cap rankings as of November 3, 2026. Also see ANEB asset base for a full breakdown of the balance sheet.
Key companies related to Anebulo Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Anebulo Pharmaceuticals Inc (2021–2026)
Market capitalization of Anebulo Pharmaceuticals Inc from 2021 to today. Between 2021 and today, Anebulo Pharmaceuticals Inc's market cap moved from $250.83 Million to $ 13.52 Million, with a yearly change of -43.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.52 Million | -67.18% |
| 2025 | $41.19 Million | -39.88% |
| 2024 | $68.52 Million | -30.58% |
| 2023 | $98.70 Million | -0.17% |
| 2022 | $98.86 Million | -60.59% |
| 2021 | $250.83 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Anebulo Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.52 Million USD |
| MoneyControl | $13.52 Million USD |
| MarketWatch | $13.52 Million USD |
| marketcap.company | $13.52 Million USD |
| Reuters | $13.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more